{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T13:42:23Z","timestamp":1790430143991,"version":"4.1.0"},"reference-count":104,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T00:00:00Z","timestamp":1603411200000},"content-version":"vor","delay-in-days":121,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-AG50603"],"award-info":[{"award-number":["R01-AG50603"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R37 AG011378"],"award-info":[{"award-number":["R37 AG011378"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RO1 AG041851"],"award-info":[{"award-number":["RO1 AG041851"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AG056366"],"award-info":[{"award-number":["R01 AG056366"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 NS097495"],"award-info":[{"award-number":["R01 NS097495"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01 AG06786"],"award-info":[{"award-number":["U01 AG06786"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AG034676"],"award-info":[{"award-number":["R01 AG034676"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50 AG016574"],"award-info":[{"award-number":["P50 AG016574"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Alexander Family Professorship of Alzheimer\u2019s Disease Research"},{"DOI":"10.13039\/100000867","name":"Robert Wood Johnson Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000867","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016293","name":"The Elsie and Marvin Dekelboum Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016293","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Liston Family Foundation"},{"DOI":"10.13039\/100015595","name":"GHR Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015595","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Foundation Dr. Corinne Schuler"},{"DOI":"10.13039\/100000957","name":"Alzheimer\u2019s Association","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007048","name":"Mayo Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Clinical trials with anti-tau drugs will need to target individuals at risk of accumulating tau. Our objective was to identify variables available in a research setting that predict future rates of tau PET accumulation separately among individuals who were either cognitively unimpaired or cognitively impaired. All 337 participants had: a baseline study visit with MRI, amyloid PET, and tau PET exams, at least one follow-up tau PET exam; and met clinical criteria for membership in one of two clinical diagnostic groups: cognitively unimpaired (n\u2009=\u2009203); or cognitively impaired (n\u2009=\u2009134, a combined group of participants with either mild cognitive impairment or dementia with Alzheimer\u2019s clinical syndrome). Our primary analyses were in these two clinical groups; however, we also evaluated subgroups dividing the unimpaired group by normal\/abnormal amyloid PET and the impaired group by clinical phenotype (mild cognitive impairment, amnestic dementia, and non-amnestic dementia). Linear mixed effects models were used to estimate associations between age, sex, education, APOE genotype, amyloid and tau PET standardized uptake value ratio (SUVR), cognitive performance, cortical thickness, and white matter hyperintensity volume at baseline, and the rate of subsequent tau PET accumulation. Log-transformed tau PET SUVR was used as the response and rates were summarized as annual per cent change. A temporal lobe tau PET meta-region of interest was used. In the cognitively unimpaired group, only higher baseline amyloid PET was a significant independent predictor of higher tau accumulation rates (P\u2009&amp;lt;\u20090.001). Higher rates of tau accumulation were associated with faster rates of cognitive decline in the\u00a0cognitively unimpaired subgroup with abnormal amyloid PET (P\u2009=\u20090.03), but among the subgroup with normal amyloid PET. In the cognitively impaired group, younger age (P\u2009=\u20090.02), higher baseline amyloid PET (P\u2009=\u20090.05), APOE \u03b54 (P\u2009=\u20090.05), and better cognitive performance (P\u2009=\u20090.05) were significant independent predictors of higher tau accumulation rates. Among impaired individuals, faster cognitive decline was associated with faster rates of tau accumulation (P\u2009=\u20090.01). While we examined many possible predictor variables, our results indicate that screening of unimpaired individuals for potential inclusion in anti-tau trials may be straightforward because the only independent predictor of high tau rates was amyloidosis. In cognitively impaired individuals, imaging and clinical variables consistent with early onset Alzheimer\u2019s disease phenotype were associated with higher rates of tau PET accumulation suggesting this may be a highly advantageous group in which to conduct proof-of-concept clinical trials that target tau-related mechanisms. The nature of the dementia phenotype (amnestic versus non-amnestic) did not affect this conclusion.<\/jats:p>","DOI":"10.1093\/brain\/awaa248","type":"journal-article","created":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T23:32:21Z","timestamp":1594769541000},"page":"3136-3150","source":"Crossref","is-referenced-by-count":112,"title":["Predicting future rates of tau accumulation on PET"],"prefix":"10.1093","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7916-622X","authenticated-orcid":false,"suffix":"Jr","given":"Clifford R","family":"Jack","sequence":"first","affiliation":[{"name":"Department of Radiology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather J","family":"Wiste","sequence":"additional","affiliation":[{"name":"Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D","family":"Weigand","sequence":"additional","affiliation":[{"name":"Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry M","family":"Therneau","sequence":"additional","affiliation":[{"name":"Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val J","family":"Lowe","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S","family":"Knopman","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4390-685X","authenticated-orcid":false,"given":"Hugo","family":"Botha","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2770-0691","authenticated-orcid":false,"given":"Jonathan","family":"Graff-Radford","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T","family":"Jones","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanis J","family":"Ferman","sequence":"additional","affiliation":[{"name":"Department of Psychology, Mayo Clinic, Jacksonville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4153-8187","authenticated-orcid":false,"given":"Bradley F","family":"Boeve","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kejal","family":"Kantarci","sequence":"additional","affiliation":[{"name":"Department of Radiology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashanthi","family":"Vemuri","sequence":"additional","affiliation":[{"name":"Department of Radiology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7177-1185","authenticated-orcid":false,"given":"Michelle M","family":"Mielke","sequence":"additional","affiliation":[{"name":"Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Whitwell","sequence":"additional","affiliation":[{"name":"Department of Radiology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2930-8634","authenticated-orcid":false,"given":"Keith","family":"Josephs","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G","family":"Schwarz","sequence":"additional","affiliation":[{"name":"Department of Radiology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew L","family":"Senjem","sequence":"additional","affiliation":[{"name":"Department of Radiology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L","family":"Gunter","sequence":"additional","affiliation":[{"name":"Department of Radiology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald C","family":"Petersen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,6,24]]},"reference":[{"key":"2020102603511083300_awaa248-B1","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/ana.24135","article-title":"Sex modifies the APOE-related risk of developing Alzheimer disease","volume":"75","author":"Altmann","year":"2014","journal-title":"Ann Neurol"},{"key":"2020102603511083300_awaa248-B2","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1212\/WNL.53.9.1992","article-title":"Gender differences in the incidence of AD and vascular dementia: the EURODEM Studies. EURODEM Incidence Research Group","volume":"53","author":"Andersen","year":"1999","journal-title":"Neurology"},{"key":"2020102603511083300_awaa248-B3","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1212\/WNL.42.3.631","article-title":"Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease","volume":"42","author":"Arriagada","year":"1992","journal-title":"Neurology"},{"key":"2020102603511083300_awaa248-B4","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/s41591-020-0781-z","article-title":"A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease","volume":"26","author":"Barthelemy","year":"2020","journal-title":"Nat Med"},{"key":"2020102603511083300_awaa248-B5","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/ana.22333","article-title":"Amyloid-beta associated cortical thinning in clinically normal elderly","volume":"69","author":"Becker","year":"2011","journal-title":"Ann Neurol"},{"key":"2020102603511083300_awaa248-B6","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1093\/brain\/awx243","article-title":"Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease","volume":"140","author":"Bejanin","year":"2017","journal-title":"Brain"},{"key":"2020102603511083300_awaa248-B7","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1001\/archneur.61.3.378","article-title":"Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function","volume":"61","author":"Bennett","year":"2004","journal-title":"Arch Neurol"},{"key":"2020102603511083300_awaa248-B8","doi-asserted-by":"crossref","first-page":"e940","DOI":"10.1212\/WNL.0000000000005124","article-title":"Tau-negative amnestic dementia masquerading as Alzheimer disease dementia","volume":"90","author":"Botha","year":"2018","journal-title":"Neurology"},{"key":"2020102603511083300_awaa248-B9","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1093\/brain\/awy049","article-title":"FDG-PET in tau-negative amnestic dementia resembles that of autopsy-proven hippocampal sclerosis","volume":"141","author":"Botha","year":"2018","journal-title":"Brain"},{"key":"2020102603511083300_awaa248-B10","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf2362","article-title":"Tau and A\u03b2 imaging, CSF measures, and cognition in Alzheimer\u2019s disease","volume":"8","author":"Brier","year":"2016","journal-title":"Sci Transl Med"},{"key":"2020102603511083300_awaa248-B11","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jalz.2010.11.007","article-title":"National estimates of the prevalence of Alzheimer's disease in the United States","volume":"7","author":"Brookmeyer","year":"2011","journal-title":"Alzheimers Dement"},{"key":"2020102603511083300_awaa248-B12","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S1474-4422(16)30125-9","article-title":"Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study","volume":"15","author":"Burnham","year":"2016","journal-title":"Lancet Neurol"},{"key":"2020102603511083300_awaa248-B13","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1038\/mp.2017.108","article-title":"Longitudinal changes of tau PET imaging in relation to hypometabolism in prodromal and Alzheimer's disease dementia","volume":"23","author":"Chiotis","year":"2018","journal-title":"Mol Psychiatry"},{"key":"2020102603511083300_awaa248-B14","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/ana.24711","article-title":"In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum","volume":"80","author":"Cho","year":"2016","journal-title":"Ann Neurol"},{"key":"2020102603511083300_awaa248-B15","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1212\/WNL.0000000000002892","article-title":"Tau PET in Alzheimer disease and mild cognitive impairment","volume":"87","author":"Cho","year":"2016","journal-title":"Neurology"},{"key":"2020102603511083300_awaa248-B16","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.neurobiolaging.2017.01.024","article-title":"Excessive tau accumulation in the parieto-occipital cortex characterizes early-onset Alzheimer's disease","volume":"53","author":"Cho","year":"2017","journal-title":"Neurobiol Aging"},{"key":"2020102603511083300_awaa248-B17","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.2967\/jnumed.118.221697","article-title":"Progressive Tau Accumulation in Alzheimer Disease: 2-Year Follow-up Study","volume":"60","author":"Cho","year":"2019","journal-title":"J Nucl Med"},{"key":"2020102603511083300_awaa248-B18","volume-title":"Visualizing data","author":"Cleveland","year":"1993"},{"key":"2020102603511083300_awaa248-B19","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.jalz.2017.01.014","article-title":"Consensus classification of posterior cortical atrophy","volume":"13","author":"Crutch","year":"2017","journal-title":"Alzheimers Dement"},{"key":"2020102603511083300_awaa248-B20","first-page":"157","article-title":"Anti-Tau trials for Alzheimer's disease: a report from the EU\/US\/CTAD Task Force","volume":"6","author":"Cummings","year":"2019","journal-title":"J Prev Alzheimers Dis"},{"key":"2020102603511083300_awaa248-B21","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.trci.2019.05.008","article-title":"Alzheimer's disease drug development pipeline: 2019","volume":"5","author":"Cummings","year":"2019","journal-title":"Alzheimer's Dement"},{"key":"2020102603511083300_awaa248-B22","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1001\/jama.2017.6669","article-title":"Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons","volume":"317","author":"Donohue","year":"2017","journal-title":"JAMA"},{"key":"2020102603511083300_awaa248-B23","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1001\/archneur.59.10.1589","article-title":"Dementia and Alzheimer disease incidence rates do not vary by sex in Rochester, Minn","volume":"59","author":"Edland","year":"2002","journal-title":"Arch Neurol"},{"key":"2020102603511083300_awaa248-B24","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1001\/jama.1997.03550160069041","article-title":"Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium","volume":"278","author":"Farrer","year":"1997","journal-title":"JAMA"},{"key":"2020102603511083300_awaa248-B25","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1017\/cjn.2016.36","article-title":"The prevalence and incidence of dementia due to Alzheimer's disease: a systematic review and meta-analysis","volume":"43","author":"Fiest","year":"2016","journal-title":"Can J Neurol Sci"},{"key":"2020102603511083300_awaa248-B26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neurobiolaging.2012.04.017","article-title":"Apolipoprotein E epsilon4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease","volume":"34","author":"Fleisher","year":"2013","journal-title":"Neurobiol Aging"},{"key":"2020102603511083300_awaa248-B27","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41467-019-14159-1","article-title":"Functional brain architecture is associated with the rate of tau accumulation in Alzheimer's disease","volume":"11","author":"Franzmeier","year":"2020","journal-title":"Nat Commun"},{"key":"2020102603511083300_awaa248-B28","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1198\/000313006X152649","article-title":"The difference between \u201csignificant\u201d and \u201cnot significant\u201d is not itself statistically significant","volume":"60","author":"Gelman","year":"2006","journal-title":"Am Stat"},{"key":"2020102603511083300_awaa248-B29","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/ana.410410106","article-title":"Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease","volume":"41","author":"Gomez-Isla","year":"1997","journal-title":"Ann Neurol"},{"key":"2020102603511083300_awaa248-B30","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/brain\/awz019","article-title":"Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers","volume":"142","author":"Gordon","year":"2019","journal-title":"Brain"},{"key":"2020102603511083300_awaa248-B31","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.dadm.2018.02.003","article-title":"Cross-sectional and longitudinal atrophy is preferentially associated with tau rather than amyloid beta positron emission tomography pathology","volume":"10","author":"Gordon","year":"2018","journal-title":"Alzheimers Dement (Amst)"},{"key":"2020102603511083300_awaa248-B32","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1212\/WNL.0b013e31821103e6","article-title":"Classification of primary progressive aphasia and its variants","volume":"76","author":"Gorno-Tempini","year":"2011","journal-title":"Neurology"},{"key":"2020102603511083300_awaa248-B33","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1093\/brain\/awz162","article-title":"White matter hyperintensities: relationship to amyloid and tau burden","volume":"142","author":"Graff-Radford","year":"2019","journal-title":"Brain"},{"key":"2020102603511083300_awaa248-B34","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1001\/jamaneurol.2019.1424","article-title":"Association of amyloid and tau with cognition in preclinical Alzheimer disease: a longitudinal study","volume":"76","author":"Hanseeuw","year":"2019","journal-title":"JAMA Neurol"},{"key":"2020102603511083300_awaa248-B35","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/ana.25406","article-title":"Longitudinal tau accumulation and atrophy in aging and alzheimer disease","volume":"85","author":"Harrison","year":"2019","journal-title":"Ann Neurol"},{"key":"2020102603511083300_awaa248-B36","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1097\/00001756-200210070-00028","article-title":"Age at onset is associated with disease severity in Lewy body variant and Alzheimer's disease","volume":"13","author":"Ho","year":"2002","journal-title":"Neuroreport"},{"key":"2020102603511083300_awaa248-B37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","article-title":"National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease","volume":"8","author":"Hyman","year":"2012","journal-title":"Alzheimers Dement"},{"key":"2020102603511083300_awaa248-B38","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"key":"2020102603511083300_awaa248-B39","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1093\/brain\/awz268","article-title":"The bivariate distribution of amyloid-beta and tau: relationship with established neurocognitive clinical syndromes","volume":"142","author":"Jack","year":"2019","journal-title":"Brain"},{"key":"2020102603511083300_awaa248-B40","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1093\/brain\/awy059","article-title":"Longitudinal tau PET in ageing and Alzheimer's disease","volume":"141","author":"Jack","year":"2018","journal-title":"Brain"},{"key":"2020102603511083300_awaa248-B41","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1001\/jama.2019.7437","article-title":"Associations of amyloid, tau, and neurodegeneration biomarker profiles with rates of memory decline among individuals without dementia","volume":"321","author":"Jack","year":"2019","journal-title":"JAMA"},{"key":"2020102603511083300_awaa248-B42","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jalz.2016.08.005","article-title":"Defining imaging biomarker cut points for brain aging and Alzheimer's disease","volume":"13","author":"Jack","year":"2017","journal-title":"Alzheimers Dement"},{"key":"2020102603511083300_awaa248-B43","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40478-019-0664-z","article-title":"A walk through tau therapeutic strategies","volume":"7","author":"Jadhav","year":"2019","journal-title":"Acta Neuropathol Commun"},{"key":"2020102603511083300_awaa248-B44","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2015.4668","article-title":"Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis","volume":"313","author":"Jansen","year":"2015","journal-title":"JAMA"},{"key":"2020102603511083300_awaa248-B45","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1001\/jamapsychiatry.2017.3391","article-title":"Association of cerebral amyloid-beta aggregation with cognitive functioning in persons without dementia","volume":"75","author":"Jansen","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"2020102603511083300_awaa248-B46","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/ana.24546","article-title":"Tau positron emission tomographic imaging in aging and early Alzheimer's disease","volume":"79","author":"Johnson","year":"2016","journal-title":"Ann Neurol"},{"key":"2020102603511083300_awaa248-B47","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","article-title":"Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts","volume":"19","author":"Karikari","year":"2020","journal-title":"Lancet Neurol"},{"key":"2020102603511083300_awaa248-B48","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1212\/WNL.0000000000001831","article-title":"Multiple pathologies are common and related to dementia in the oldest-old: the 90+ Study","volume":"85","author":"Kawas","year":"2015","journal-title":"Neurology"},{"key":"2020102603511083300_awaa248-B49","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13195-019-0559-z","article-title":"Gantenerumab reduces amyloid-beta plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis","volume":"11","author":"Klein","year":"2019","journal-title":"Alzheimers Res Ther"},{"key":"2020102603511083300_awaa248-B50","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ana.20009","article-title":"Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B","volume":"55","author":"Klunk","year":"2004","journal-title":"Ann Neurol"},{"key":"2020102603511083300_awaa248-B51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","article-title":"The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET","volume":"11","author":"Klunk","year":"2015","journal-title":"Alzheimer's Dementia"},{"key":"2020102603511083300_awaa248-B52","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1093\/brain\/awz025","article-title":"Entorhinal cortex tau, amyloid-beta, cortical thickness and memory performance in non-demented subjects","volume":"142","author":"Knopman","year":"2019","journal-title":"Brain"},{"key":"2020102603511083300_awaa248-B53","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1001\/archneur.1991.00530190071018","article-title":"The short test of mental status. Correlations with standardized psychometric testing","volume":"48","author":"Kokmen","year":"1991","journal-title":"Arch Neurol"},{"key":"2020102603511083300_awaa248-B54","first-page":"e12007","article-title":"Amyloid duration is associated with preclinical cognitive decline and tau PET","volume":"12","author":"Koscik","year":"2019","journal-title":"bioRxiv"},{"key":"2020102603511083300_awaa248-B55","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1212\/WNL.46.1.136","article-title":"Clinical and neuropsychological differences between patients with earlier and later onset of Alzheimer's disease: a CERAD analysis, Part XII","volume":"46","author":"Koss","year":"1996","journal-title":"Neurology"},{"key":"2020102603511083300_awaa248-B56","doi-asserted-by":"crossref","first-page":"eaau5732","DOI":"10.1126\/scitranslmed.aau5732","article-title":"Prospective longitudinal atrophy in Alzheimer's disease correlates with the intensity and topography of baseline tau-PET","volume":"12","author":"La Joie","year":"2020","journal-title":"Sci Transl Med"},{"key":"2020102603511083300_awaa248-B57","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/s41380-018-0342-8","article-title":"Tau PET imaging in neurodegenerative tauopathies-still a challenge","volume":"24","author":"Leuzy","year":"2019","journal-title":"Mol Psychiatry"},{"key":"2020102603511083300_awaa248-B58","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/brain\/awt286","article-title":"Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease","volume":"137","author":"Lim","year":"2014","journal-title":"Brain"},{"key":"2020102603511083300_awaa248-B59","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","article-title":"Alzheimer disease: an update on pathobiology and treatment strategies","volume":"179","author":"Long","year":"2019","journal-title":"Cell"},{"key":"2020102603511083300_awaa248-B60","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/brain\/awx320","article-title":"Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia","volume":"141","author":"Lowe","year":"2018","journal-title":"Brain"},{"key":"2020102603511083300_awaa248-B61","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.neuroimage.2017.05.058","article-title":"Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease","volume":"157","author":"Maass","year":"2017","journal-title":"Neuroimage"},{"key":"2020102603511083300_awaa248-B62","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1212\/WNL.0000000000001375","article-title":"Brain structure and function as mediators of the effects of amyloid on memory","volume":"84","author":"Mattsson","year":"2015","journal-title":"Neurology"},{"key":"2020102603511083300_awaa248-B63","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1001\/jamaneurol.2017.4026","article-title":"Tau Positron Emission Tomography in Autosomal Dominant Alzheimer Disease: small Windows, Big Picture","volume":"75","author":"McDade","year":"2018","journal-title":"JAMA Neurol"},{"key":"2020102603511083300_awaa248-B64","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Assocation Workgroup","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"key":"2020102603511083300_awaa248-B65","first-page":"2053","article-title":"Comparative evaluation of MR-based partial-volume correction schemes for PET","volume":"40","author":"Meltzer","year":"1999","journal-title":"J Nucl Med"},{"key":"2020102603511083300_awaa248-B66","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","article-title":"Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography","volume":"14","author":"Mielke","year":"2018","journal-title":"Alzheimers Dement"},{"key":"2020102603511083300_awaa248-B67","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1212\/WNL.0b013e31826e2696","article-title":"Indicators of amyloid burden in a population-based study of cognitively normal elderly","volume":"79","author":"Mielke","year":"2012","journal-title":"Neurology"},{"key":"2020102603511083300_awaa248-B68","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.neuroimage.2017.07.050","article-title":"AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: defining a summary measure","volume":"161","author":"Mishra","year":"2017","journal-title":"Neuroimage"},{"key":"2020102603511083300_awaa248-B69","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.jalz.2017.01.018","article-title":"Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid beta","volume":"13","author":"Mormino","year":"2017","journal-title":"Alzheimers Dement"},{"key":"2020102603511083300_awaa248-B70","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","article-title":"The Clinical Dementia Rating (CDR): current version and scoring rules","volume":"43","author":"Morris","year":"1993","journal-title":"Neurology"},{"key":"2020102603511083300_awaa248-B71","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature25456","article-title":"High performance plasma amyloid-\u03b2 biomarkers for Alzheimer\u2019s disease","volume":"554","author":"Nakamura","year":"2018","journal-title":"Nature"},{"key":"2020102603511083300_awaa248-B72","first-page":"695","article-title":"The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc","author":"Nasreddine","year":"2005"},{"key":"2020102603511083300_awaa248-B73","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/NEN.0b013e31825018f7","article-title":"Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature","volume":"71","author":"Nelson","year":"2012","journal-title":"J Neuropathol Exp Neurol"},{"key":"2020102603511083300_awaa248-B74","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1093\/brain\/awz099","article-title":"Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report","volume":"142","author":"Nelson","year":"2019","journal-title":"Brain"},{"key":"2020102603511083300_awaa248-B75","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s00401-011-0826-y","article-title":"Alzheimer's disease is not \u201cbrain aging\u201d: neuropathological, genetic, and epidemiological human studies","volume":"121","author":"Nelson","year":"2011","journal-title":"Acta Neuropathol"},{"key":"2020102603511083300_awaa248-B76","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1001\/jamaneurol.2017.2188","article-title":"Apolipoprotein E Genotype and Sex Risk Factors for Alzheimer Disease: A Meta-analysis","volume":"74","author":"Neu","year":"2017","journal-title":"JAMA Neurol"},{"key":"2020102603511083300_awaa248-B77","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jalz.2019.08.201","article-title":"Distinct tau PET patterns in atrophy-defined subtypes of Alzheimer's disease","volume":"16","author":"Ossenkoppele","year":"2019","journal-title":"Alzheimers Dement"},{"key":"2020102603511083300_awaa248-B78","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1001\/jama.2018.12917","article-title":"Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders","volume":"320","author":"Ossenkoppele","year":"2018","journal-title":"JAMA"},{"key":"2020102603511083300_awaa248-B79","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/brain\/aww027","article-title":"Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease","volume":"139","author":"Ossenkoppele","year":"2016","journal-title":"Brain"},{"key":"2020102603511083300_awaa248-B80","doi-asserted-by":"crossref","first-page":"e601","DOI":"10.1212\/WNL.0000000000006875","article-title":"Associations between tau, Abeta, and cortical thickness with cognition in Alzheimer disease","volume":"92","author":"Ossenkoppele","year":"2019","journal-title":"Neurology"},{"key":"2020102603511083300_awaa248-B81","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jalz.2017.06.2266","article-title":"Amyloid beta concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis","volume":"13","author":"Ovod","year":"2017","journal-title":"Alzheimers Dement"},{"key":"2020102603511083300_awaa248-B82","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2796.2004.01388.x","article-title":"Mild cognitive impairment as a diagnostic entity","volume":"256","author":"Petersen","year":"2004","journal-title":"J Intern Med"},{"key":"2020102603511083300_awaa248-B83","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1093\/brain\/awz090","article-title":"A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia","volume":"142","author":"Pontecorvo","year":"2019","journal-title":"Brain"},{"key":"2020102603511083300_awaa248-B84","first-page":"748","article-title":"Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition","volume":"140","author":"Pontecorvo","year":"2017","journal-title":"Brain"},{"key":"2020102603511083300_awaa248-B85","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000115751","article-title":"The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics","volume":"30","author":"Roberts","year":"2008","journal-title":"Neuroepidemiology"},{"key":"2020102603511083300_awaa248-B86","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.neuron.2016.01.028","article-title":"PET Imaging of tau deposition in the aging human brain","volume":"89","author":"Scholl","year":"2016","journal-title":"Neuron"},{"key":"2020102603511083300_awaa248-B87","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1093\/brain\/awx171","article-title":"Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer's disease","volume":"140","author":"Scholl","year":"2017","journal-title":"Brain"},{"key":"2020102603511083300_awaa248-B88","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3233\/JAD-180749","article-title":"A comparison of partial volume correction techniques for measuring change in serial amyloid PET SUVR","volume":"67","author":"Schwarz","year":"2019","journal-title":"Jad"},{"key":"2020102603511083300_awaa248-B89","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.nicl.2016.05.017","article-title":"A large-scale comparison of cortical thickness and volume methods for measuring Alzheimer's disease severity","volume":"11","author":"Schwarz","year":"2016","journal-title":"NeuroImage: Clin"},{"key":"2020102603511083300_awaa248-B90","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces Abeta plaques in Alzheimer's disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"2020102603511083300_awaa248-B91","doi-asserted-by":"crossref","first-page":"101823","DOI":"10.1016\/j.nicl.2019.101823","article-title":"Longitudinal tau-PET uptake and atrophy in atypical Alzheimer's disease","volume":"23","author":"Sintini","year":"2019","journal-title":"Neuroimage Clin"},{"key":"2020102603511083300_awaa248-B92","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.neurobiolaging.2012.06.014","article-title":"Amyloid deposition detected with florbetapir F 18 [(18)F-AV-45] is related to lower episodic memory performance in clinically normal older individuals","volume":"34","author":"Sperling","year":"2013","journal-title":"Neurobiol Aging"},{"key":"2020102603511083300_awaa248-B93","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/ana.25395","article-title":"The impact of amyloid-beta and tau on prospective cognitive decline in older individuals","volume":"85","author":"Sperling","year":"2019","journal-title":"Ann Neurol"},{"key":"2020102603511083300_awaa248-B94","doi-asserted-by":"crossref","first-page":"228fs13","DOI":"10.1126\/scitranslmed.3007941","article-title":"The A4 study: stopping AD before symptoms begin?","volume":"6","author":"Sperling","year":"2014","journal-title":"Sci Transl Med"},{"key":"2020102603511083300_awaa248-B95","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1093\/ije\/dys195","article-title":"Data resource profile: the Rochester Epidemiology Project (REP) medical records-linkage system","volume":"41","author":"St Sauver","year":"2012","journal-title":"Int J Epidemiol"},{"key":"2020102603511083300_awaa248-B96","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","article-title":"Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration","volume":"26","author":"Thijssen","year":"2020","journal-title":"Nat Med"},{"key":"2020102603511083300_awaa248-B97","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.jalz.2016.03.009","article-title":"Amyloid status imputed from a multimodal classifier including structural MRI distinguishes progressors from nonprogressors in a mild Alzheimer's disease clinical trial cohort","volume":"12","author":"Tosun","year":"2016","journal-title":"Alzheimers Dement"},{"key":"2020102603511083300_awaa248-B98","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcaa068","article-title":"Progressive dysexecutive syndrome due to alzheimer\u2019s disease: a description of 55 cases and comparison to other phenotypes","author":"Townley","year":"2020","journal-title":"Brain Commun"},{"key":"2020102603511083300_awaa248-B99","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.mayocp.2019.01.043","article-title":"Comparison of the short test of mental status and the montreal cognitive assessment across the cognitive spectrum","volume":"94","author":"Townley","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"2020102603511083300_awaa248-B100","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1474-4422(13)70044-9","article-title":"Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study","volume":"12","author":"Villemagne","year":"2013","journal-title":"Lancet Neurol"},{"key":"2020102603511083300_awaa248-B101","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1016\/j.neurobiolaging.2015.08.029","article-title":"Suspected non-AD pathology in mild cognitive impairment","volume":"36","author":"Wisse","year":"2015","journal-title":"Neurobiol Aging"},{"key":"2020102603511083300_awaa248-B102","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jalz.2011.07.003","article-title":"Amyloid imaging in dementias with atypical presentation","volume":"8","author":"Wolk","year":"2012","journal-title":"Alzheimers Dement"},{"key":"2020102603511083300_awaa248-B103","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.jalz.2012.11.008","article-title":"18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease","volume":"9","author":"Xia","year":"2013","journal-title":"Alzheimers Dement"},{"key":"2020102603511083300_awaa248-B104","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/jamaneurol.2016.5755","article-title":"Association of In Vivo [18F]AV-1451 Tau PET imaging results with cortical atrophy and symptoms in typical and atypical Alzheimer disease","volume":"74","author":"Xia","year":"2017","journal-title":"JAMA Neurol"}],"container-title":["Brain"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/brain\/article-pdf\/143\/10\/3136\/34032320\/awaa248.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/brain\/article-pdf\/143\/10\/3136\/34032320\/awaa248.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T03:29:15Z","timestamp":1696390155000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/brain\/article\/143\/10\/3136\/5930009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,24]]},"references-count":104,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,6,24]]},"published-print":{"date-parts":[[2020,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/brain\/awaa248","relation":{},"ISSN":["0006-8950","1460-2156"],"issn-type":[{"value":"0006-8950","type":"print"},{"value":"1460-2156","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,10]]},"published":{"date-parts":[[2020,6,24]]}}}